(LENZ) LENZ Therapeutics, Inc. Marketing Mix Research

LENZ Therapeutics, Inc.’s two lead programs sit in late-stage Phase III, the last major step before approval. Phase III trials usually enroll hundreds of patients and are built to prove safety and efficacy at scale. Commercial sales cannot start until the FDA grants approval, so this step directly controls launch timing.

• Late-stage, near market
• Needs FDA approval first
• Phase III uses large patient sets

LENZ Therapeutics, Inc. builds its product mix around prescription ophthalmic drops, a direct-to-eye dosage form that avoids surgery and aims to improve near vision fast. In August 2025, the U.S. FDA approved VIZZ (aceclidine ophthalmic solution 1.44%), with trials showing near-vision gains within 30 minutes that could last up to 10 hours.

• Prescription eye-drop delivery
• Direct ocular absorption
• Non-surgical vision support

If approved, LENZ Therapeutics, Inc.'s presbyopia drop would move through ophthalmology and optometry, the core eye-care prescriber channels for office-based starts and follow-up. Presbyopia affects about 1.8 billion people worldwide, so the channel fits a large, routine-use patient pool. The model depends on clinician trust, in-office education, and repeat prescribing, not retail self-selection.

• Ophthalmology and optometry are the main prescriber routes.
• Office visits drive first use and patient training.
• Presbyopia's global pool is about 1.8 billion.

LENZ Therapeutics, Inc. has no disclosed broad consumer retail distribution, so "place" is still centered on research, clinical execution, and future launch planning. In FY2025, the Company remained development-stage and not a mass-market seller, so it did not need a retail shelf network or consumer storefronts. Any near-term rollout will likely depend on medical channels, not retail stores.

• No broad retail footprint is disclosed.
• FY2025 remained development-stage.
• Place focus: research and launch prep.

LENZ Therapeutics uses investor relations as its core promotion tool because it is still pre-commercial, so the market tracks pipeline milestones, cash use, and financing needs rather than sales. For biopharma, every trial update can shift valuation, especially before any product revenue starts.

• Pre-commercial firms sell progress, not product.
• Trial news drives value creation.
• Investor updates support funding access.

Physician education is the key promotion lever for LENZ Therapeutics, Inc.'s presbyopia launch. Presbyopia affects about 1.8 billion people worldwide, so eye-care providers will need clear, evidence-led guidance on dosing, benefits, and safety before prescribing.

• Build trust with trial-backed data.
• Explain dosing in plain terms.
• Show safety and benefit balance.

LENZ Therapeutics, Inc.’s payer coverage will likely drive adoption, because presbyopia drugs are still viewed as convenience buys unless insurers and PBMs back them. U.S. vision plans often cap routine benefits near $150-$300 a year, so out-of-pocket sensitivity is high, and a premium price will need clear payer value to win broad coverage.

• Coverage can shape uptake fast.
• Out-of-pocket cost matters most.
• Pricing must fit payer acceptance.

In specialty prescription markets, patient support often includes copay help and access services after launch, which can improve starts and persistence. For LENZ Therapeutics, Inc., no specific pricing support or affordability program is disclosed in the provided information, so the exact patient cost offset is unclear. That makes post-launch access a key watch item.

• No disclosed LENZ copay program
• Support can ease launch access
• Specialty drugs often use affordability help